

MAR 26 2002

K020862

Special 510(k)
I-Flow Elastomeric Pump

SPECIAL 510(K) - SUMMARY OF SAFETY AND EFFECTIVENESS

March 15, 2002

Submitter: I-Flow Corporation
20202 Windrow Drive
Lake Forest, CA 92630

Contact: Shane Noehre
Manager, Regulatory Affairs
I-Flow Corporation

Trade Name: I-Flow Elastomeric Pump

Common Name: Infusion Pump and Administration Set

Classification Name: Pump, Infusion

Existing Device: I-Flow Elastomeric Pump (K932740, K944692, K984502, K991513, K992072, and K020660 (pending)).

Device Description: The I-Flow Elastomeric Pump consists of an elastomeric pressure source with an integrated administration line. This special 510(k) proposes a change from latex to polyisoprene for the outer bladder. The outer bladder is not in contact with the fluid path and thus does not require biocompatibility. The inner bladder will remain the same and thus drug compatibility will not be affected.

Technology Comparison: There is no change in technology. The latex and polyisoprene bladder are two different types of elastomers with similar properties.

Conclusion: The I-Flow Elastomeric Pump with polyisoprene bladder is substantially equivalent to the existing I-Flow Elastomeric Pump with latex bladder.



MAR 26 2002

Food and Drug Administration
9200 Corporate Boulevard
Rockville MD 20850

Mr. Shane Noehre
Manager, Regulatory Affairs
I-Flow Corporation
20202 Windrow Drive
Lake Forest, California 92630

Re: K020862
Trade/Device Name: I-Flow Elastomeric Pump
Regulation Number: 880.5725
Regulation Name: Infusion Pump
Regulatory Class: II
Product Code: MEB
Dated: March 15, 2002
Received: March 18, 2002

Dear Mr. Noehre:

We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration.

If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to such additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 898. In addition, FDA may publish further announcements concerning your device in the Federal Register.

Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies.

You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Part 801); good manufacturing practice requirements as set forth in the quality systems (QS) regulation (21 CFR Part 820); and if applicable, the electronic product radiation control provisions (Sections 531-542 of the Act); 21 CFR 1000-1050.

This letter will allow you to begin marketing your device as described in your Section 510(k) premarket notification. The FDA finding of substantial equivalence of your device to a legally marketed predicate device results in a classification for your device and thus, permits your device to proceed to the market.

If you desire specific advice for your device on our labeling regulation (21 CFR Part 801 and additionally 21 CFR Part 809.10 for in vitro diagnostic devices), please contact the Office of Compliance at (301) 594-4618. Additionally, for questions on the promotion and advertising of your device, please contact the Office of Compliance at (301) 594-4639. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21CFR Part 807.97). Other general information on your responsibilities under the Act may be obtained from the Division of Small Manufacturers, International and Consumer Assistance at its toll-free number (800) 638-2041 or (301) 443-6597 or at its Internet address <http://www.fda.gov/cdrh/dsma/dsmamain.html>

Sincerely yours,



P/ Timothy A. Ulatowski
Director
Division of Dental, Infection Control
and General Hospital Devices
Office of Device Evaluation
Center for Devices and
Radiological Health

Enclosure



I-Flow Corporation

20202 Windrow Drive
Lake Forest, CA 92630
Tel: 800.448.3569 or 949.206.2700
Fax: 949.206.2600
www.i-flowcorp.com

Ver/ 3 - 4/24/96

Applicant: I-Flow Corporation

510(k) Number (if known): _____

Device Name: I-Flow Elastomeric Pump

Indications For Use:

1. The I-Flow Elastomeric Pump is intended for continuous and/or intermittent infusion of medications for general infusion use, including antibiotic delivery, chemotherapy and pain management. Routes of administration include the following: intravenous, intra-arterial, subcutaneous, intramuscular and epidural.
2. The I-Flow Elastomeric Pump is also intended for continuous and/or intermittent delivery of medication (such as local anesthetics or narcotics) to surgical wound sites and/or close proximity to nerves for preoperative, perioperative and postoperative regional anesthesia and pain management. Routes of administration may be intraoperative, perineural or percutaneous.

(PLEASE DO NOT WRITE BELOW THIS LINE - CONTINUE ON ANOTHER PAGE IF NEEDED)

Concurrence of CDRH, Office of Device Evaluation (ODE)

(Per 21 CFR 801.109)

(Optional Format 1-2-96)

Robert Curcio
(Division Sign-Off)

Division of Dental, Infection Control,
and General Hospital Devices

File No. Number 4020862